Pipeline

Overview

Overview

Industry leading TCR pipeline targeting solid tumors

Cancer is a leading cause of death worldwide and is characterized by the uncontrolled growth of abnormal cells whose ability to evade the immune system is key. Adaptimmune’s affinity enhanced T-cell therapies work with the immune system to improve detection and targeting of cancer cells, resulting in the destruction of those cancer cells. We believe that the unique potential of immunotherapy will revolutionize the treatment of oncology in the future and Adaptimmune is at the forefront of immunotherapy development. 

SPEAR® T-cell therapies targeting MAGE-A4, and AFP are progressing through clinical studies in multiple solid tumors. The clinical studies for SPEAR® T-cell therapies targeting MAGE-A10 have been closed.

Our Pipeline

Adaptimmune is developing an industry-leading T-cell therapy pipeline in solid tumors, and has a deep pipeline of identified and proprietary targets for further product development.

Low-radiation Sub-study (ADP-A2M4)

This is a Phase 1, single-center sub-study to characterize safety and tolerability and assess anti-tumor activity of low dose radiation in combination with ADP-A2M4 across multiple tumor types. Up to 10 patients will be treated at MD Anderson Cancer Center. This is a sub-study of the ADP-A2M4 Phase 1 trial.

View Clinical Trials

SPEARHEAD-2 (afamitresgene autoleucel in combination with pembrolizumab)

This is a Phase 2, single arm clinical trial to investigate the efficacy and safety of afamitresgene autoleucel in combination with pembrolizumab in HLA-A*02 positive patients with recurrent or metastatic head and neck cancer expressing MAGE-A4.

View Clinical Trials

SURPASS (ADP-A2M4CD8) Phase 1 clinical trial

This is a Phase 1, open-label, dose escalation clinical trial to evaluate the safety and anti-tumor activity of next-generation ADP-A2M4CD8 SPEAR T-cells in patients who are HLA-A*02 positive and have inoperable locally advanced urothelial cancer, esophageal cancersgastroesophageal junction cancergastric cancer, non-small cell lung cancer (NSCLC) or head and neck cancer expressing MAGE-A4.

View Clinical Trials

ADP-A2AFP Phase 1 clinical trial

This is a Phase 1, open-label, dose escalation clinical trial designed to evaluate the safety and anti-tumor activity of Adaptimmune's ADP-A2AFP therapeutic candidate. The ongoing trial will include patients who have advanced hepatocellular carcinoma (liver cancer), which has grown or returned after being treated, and who are HLA-A*02 positive and have adequate AFP protein in blood or tumor, and whose noncancerous liver tissue has very little AFP protein. Patients who did not tolerate or refused other therapies may also participate. The primary objective of the clinical trial is to evaluate the safety and tolerability of ADP-A2AFP SPEAR T-cell therapy.

View Clinical Trials

ADP-A2M4 Phase 1 clinical trial

This is a Phase 1, open-label, dose escalation clinical trial designed to evaluate the safety and anti-tumor activity of Adaptimmune's ADP-A2M4 therapeutic candidate (now called afamitresgene autoleucel or afami-cel) in patients who are HLA-A*02 positive and have inoperable locally advanced or metastatic melanoma, urothelial cancer, head and neck cancers, ovarian cancer, non-small cell lung cancer (NSCLC), esophageal cancers, synovial sarcoma, myxoid/round cell liposarcoma (MRCLS), and gastric cancers expressing MAGE-A4. The primary objective of the clinical trial is to evaluate the safety and tolerability of ADP-A2M4. Further details are available via the link below.

Please note that this trial is not enrolling patients with the exception of the low-radiation sub-study.

View Clinical Trials

SPEARHEAD-1 (afamitresgene autoleucel)

This is a Phase 2, open-label, single arm clinical trial to evaluate the anti-tumor activity of afamitresgene autoleucel in patients who are HLA-A*02 positive and have inoperable locally advanced synovial sarcoma or myxoid/round cell liposarcoma (MRCLS) expressing MAGE-A4.

View Clinical Trials
Initiating in 2021 SURP ASS-2 Esophageal and EGJ cancers SPEARHEAD-2 Head and neck Combo with pembro Pivotal Cohort 1 enrollment complete BLA planned for 2022 SPEARHEAD-1 Syn o vial sarcoma, M R CLS Phase 2/3 Phase 1 trial Hepatocellular carcinoma SURP ASS F ocus on lung, gastroesophageal, head and neck, and bladder cancers Radiation sub-study Multiple tumors** Phase 1 trial Multiple tumors* Phase 1ADP- A2AFP ADP- A2M4CD8 Ther a p y AFPMA GE - A4 Progr am

ADP-A2M4

The ADP-A2M4 (MAGE-A4) SPEAR T-cell therapy is directed to a member of the MAGE family of cancer testis antigen expressed in many solid tumor cell types.

Learn More

ADP-A2M4CD8

Our first “next-generation therapy” is the ADP-A2M4CD8 SPEAR T-cell therapy. Unlike the ADP-A2M4CD8 SPEAR T-cells therapy, these cells also express the CD8α co-receptor alongside the engineered TCR that targets MAGE-A4.

Learn More

ADP-A2AFP

Our ADP-A2AFP product is being used to treat patients with hepatocellular carcinoma (liver cancer).

Learn More

ADP-A2M10

The ADP-A2M10 (MAGE-A10) T-cell therapy is directed to a member of the MAGE family of cancer-testis antigens expressed in several solid tumor cell types.

Learn More